← back to search

Amber Cornelius

New York University · US
Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research focused on Immune system and Immunology, with related work in Vaccination, Virology, Antibody. Notable publications include 'Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease', 'Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS – CoV ‐2 Vaccination', and 'Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals'.
h-index
citations
770
works
11
NIH funding
primary concept
email

Recent publications

SARS-CoV-2 inflammation durably imprints memory CD4 T cells
Science Immunology 2024cited by 14position: middledoi
mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection
iScience 2023cited by 24position: middledoi
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
Science Translational Medicine 2022cited by 99position: middledoi
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
Frontiers in Immunology 2022cited by 51position: middledoi
Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study
Annals of Neurology 2022cited by 26position: middledoi
Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines
Vaccines 2022cited by 26position: middledoi
Bacterial Strain–Dependent Dissociation of Cell Recruitment and Cell-to-Cell Spread in Early M. tuberculosis Infection
mBio 2022cited by 18position: middledoi
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Annals of the Rheumatic Diseases 2021cited by 266position: middledoi
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following <scp>SARS</scp>–<scp>CoV</scp>‐2 Vaccination
Arthritis & Rheumatology 2021cited by 151position: middledoi
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
mBio 2021cited by 70position: middledoi
High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
Cell Reports 2021cited by 25position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marie I. Samanovic · New York University8 papers (2021–2024)Mark J. Mulligan · NYU Langone Health8 papers (2021–2024)Ramin S. Herati · NYU Langone Health7 papers (2021–2024)Sophie L. Gray-Gaillard · New York University4 papers (2022–2024)Belinda M. Dcosta · New York University3 papers (2021–2022)Trishala Karmacharya · New York University3 papers (2022–2023)Takuya Tada · New York University3 papers (2021–2022)Nathaniel R. Landau · New York University3 papers (2021–2022)Hao Zhou · New York University3 papers (2021–2022)Sergei B. Koralov · New York University3 papers (2022–2024)Ludovic Desvignes · New York University2 papers (2022–2023)Ellie Ivanova · New York University2 papers (2023–2024)Jimmy P. Wilson · New York University2 papers (2022–2022)Michael Tuen · New York University2 papers (2022–2022)Clarice Monteiro · New York University1 papers (2024–2024)Meron F. Tasissa · New York University1 papers (2022–2022)H. Chen · New York University1 papers (2024–2024)Niels Ødum · University of Nottingham1 papers (2023–2023)Y. Patskovsky · New York University1 papers (2022–2022)Kathleen Hawker · Novartis (Switzerland)1 papers (2022–2022)